Comprehensive study to examine the effects of omalizumab in patients with bronchial asthma.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 20 Mar 2018

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Omalizumab (Primary)
Indications Asthma
Focus Biomarker; Therapeutic Use

Most Recent Events

26 Apr 2016 Results published in the Allergy
28 Feb 2012 Planned end date changed from 1 Jul 2012 to 1 Mar 2014 as reported by University Hospital Medical Information Network - Japan record.
20 Feb 2012 Additional lead trial investigator (Matsumoto H) identified as reported by University Hospital Medical Information Network - Japan record.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight